Laekna, Inc. (02105.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 6.84

From 52W high−61.16%

Volume865000.00

Market capHKD 3.26B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

HKD 6.84

From 52W high

−61.16%

Volume

865000.00

Market cap

HKD 3.26B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

58.6

MomentumView details →

1D Return

+6.14%

YTD Return

−46.66%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+6.14%

YTD Return

−46.66%

1Y Return

−48.36%

RSI (14)

58.6

vs 50D SMA

+10.15%

vs 200D SMA

−37.63%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.00

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 30, 2027 →

Latest newsMore news →

Laekna Healthcare initiated a Phase I clinical study of LAE118 for advanced solid tumors in China and enrolled the first subject.19d ago

Laekna Inc. reported interim results for the six months ended June 2026, with revenue of RMB 150 million and a net loss narrowed to RMB 2.55 million from RMB 130 million a year earlier, with no dividend declared.26d ago

Similar companies

之江生物688317.SH 申联生物688098.SH Arcus Biosciences, Inc.RCUS Veracyte, Inc.VCYT Dyne Therapeutics, Inc.DYN Arcutis Biotherapeutics, Inc.ARQT Find similar companies →

Latest newsMore news →

Laekna Healthcare initiated a Phase I clinical study of LAE118 for advanced solid tumors in China and enrolled the first subject.19d ago Laekna Inc. reported interim results for the six months ended June 2026, with revenue of RMB 150 million and a net loss narrowed to RMB 2.55 million from RMB 130 million a year earlier, with no dividend declared.26d ago Laekna (02105.HK) issued a profit alert, expecting revenue of RMB 145-155 million for the six months ending June 30, 2026, compared to zero in the prior year period, and a net loss of no more than RMB 5 million, a 96% reduction from RMB 130 million a year earlier.34d ago